ARTICLE | Clinical News

Novan genital warts treatment meets Phase II endpoint

November 29, 2016 10:24 PM UTC

Novan Inc. (NASDAQ:NOVN) gained $3.39 (14%) to $27.18 on Tuesday after it said its highest tested dose of SB206 met the primary endpoint of a Phase II study to treat genital warts caused by HPV. The company plans to begin Phase III testing of the rapid nitric oxide (NO)-releasing compound in 2H17, pending discussion with FDA.

The company said a 12% once-daily dose of SB206 met the study's primary endpoint in its intent-to-treat population, significantly improving the proportion of patients who were completely clear of warts present at baseline compared to vehicle at or before week 12 (33% for SB206 vs. 4% for vehicle, p=0.0099). The candidate also met the primary endpoint in a per-protocol analysis (42% vs. 7%, p=0.02)...

BCIQ Company Profiles

Novan Inc.